Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 60%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines Ltd is positioned for sustained long-term growth, underpinned by strong market preference for its lead product, Brukinsa, which is projected to reach peak sales of approximately $7.1 billion by 2034. With sonrotoclax demonstrating enhanced efficacy and safety profiles compared to competitors, the company's growth dynamics are further supported by an expected $3.4 billion peak sales contribution from Brukinsa and additional revenues bolstered by other therapeutic assets. The company's ongoing strategic initiatives in physician outreach and competitive contracting are anticipated to drive physician engagement, positioning BeOne Medicines towards achieving profitable operations and positive free cash flow by 2025.

Bears say

BeOne Medicines Ltd faces a negative outlook primarily due to the potential for slower-than-expected uptake of its commercial products, compounded by the risk of unsuccessful clinical trials and adverse regulatory decisions, which could limit the company's market potential. Additionally, significant cash burn associated with its pipeline raises concerns about the viability of developing marketable drugs, especially in a highly competitive oncology market where product differentiation is critical. Furthermore, geopolitical risks, along with uncertainties surrounding intellectual property protection, could further undermine the company’s competitive positioning and financial stability.

BeiGene Ltd (ONC) has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 60% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 10 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Apr 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $385.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $385.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.